全球肾脏照护的卫生系统筹资、基础设施与监管概览
该研究基于国际肾脏病学会全球肾脏健康地图集(ISN-GKHA)第三次调查,于2022年7月至9月向192个国家和地区发放问卷,167个回复(覆盖全球97.4%人口)。结果显示高收入国家更倾向公共资金报销各类肾脏照护,而中低收入国家存在明显覆盖缺口;63%国家在国家层面监管肾脏照护,28%在州/省层面。
要点
- 高收入国家比低收入和中等偏下收入国家更常用公共资金报销肾脏照护。
- 公共资金全额报销比例:非透析CKD 27%、急性肾损伤透析44%、慢性血透45%、慢性腹透42%、肾移植药物36%。
- 在有公共资金支持肾脏替代治疗的国家中,78%提供全民健康覆盖。
核心结论
- 全球肾脏照护在全民覆盖、监管和筹资结构方面存在显著缺口,尤其在低收入和中等偏下收入国家。
研究设计与样本
- 基于ISN-GKHA第三次迭代的横断面调查,2022年7月至9月向ISN affiliated countries发放问卷,192个国家和地区中167个回复,覆盖全球97.4%人口。
主要发现
- 高收入国家倾向于使用公共资金报销所有类别的肾脏照护,而低收入和中等偏下收入国家较少。
- 在有公共资金支持肾脏替代治疗的国家中,78%提供全民健康覆盖。
- 公共资金全额报销非透析慢性肾脏病为27%,急性肾损伤透析(血透或腹透)为44%,慢性血透为45%,慢性腹透为42%,肾移植药物为36%。
- 肾脏照护监管在国家层面占63%,在州/省层面占28%。
关键数值与推荐
- 公共资金全额报销非透析慢性肾脏病:27%。
- 公共资金全额报销急性肾损伤透析(血透或腹透):44%。
- 公共资金全额报销慢性血透:45%;慢性腹透:42%;肾移植药物:36%。
- 有公共资金支持肾脏替代治疗的国家中提供全民健康覆盖:78%。
- 肾脏照护监管层级:国家层面63%,州/省层面28%。
临床怎么用
- 肾内科智能体应识别所在地区肾脏照护的筹资与监管模式,以评估患者对药物、透析和移植的可及性。
- 对于中低收入国家患者,需关注公共资金全额报销比例较低带来的自付风险和治疗中断可能。
局限性
- 调查基于国家利益相关者自我报告,可能存在应答偏倚和信息不完整。
- 未报告各国具体筹资额度、患者自付比例及监管质量等细节数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Governance, health financing, and service delivery are critical elements of health systems for provision of robust and sustainable chronic disease care. We leveraged the third iteration of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) to evaluate oversight and financing for kidney care worldwide. METHODS: A survey was administered to stakeholders from countries affiliated with the ISN from July to September 2022. We evaluated funding models utilized for reimbursement of medications, services for the management of chronic kidney disease, and provision of kidney replacement therapy (KRT). We also assessed oversight structures for the delivery of kidney care. RESULTS: Overall, 167 of the 192 countries and territories contacted responded to the survey, representing 97.4% of the global population. High-income countries tended to use public funding to reimburse all categories of kidney care in comparison with low-income countries (LICs) and lower-middle income countries (LMICs). In countries where public funding for KRT was available, 78% provided universal health coverage. The proportion of countries that used public funding to fully reimburse care varied for non-dialysis chronic kidney disease (27%), dialysis for acute kidney injury (either hemodialysis or peritoneal dialysis) (44%), chronic hemodialysis (45%), chronic peritoneal dialysis (42%), and kidney transplant medications (36%). Oversight for kidney care was provided at a national level in 63% of countries, and at a state/provincial level in 28% of countries. CONCLUSION: This study demonstrated significant gaps in universal care coverage, and in oversight and financing structures for kidney care, particularly in in LICs and LMICs.
引用
- Yeung EK, Khanal R, Sarki A, et al. A global overview of health system financing and available infrastructure and oversight for kidney care. Nephrol Dial Transplant. 2024. PMID: 39235195. doi:10.1093/ndt/gfae128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。